The US Medicare Payment Advisory Commission’s initial list of ideas to overhaul payment for drugs in the physician-administered Part B setting includes applying cost-effectiveness benchmarks for new drugs and biologics approved via the Accelerated Approval pathway.
At its 7 October meeting, MedPAC began consideration of proposals to address the “high prices” of drugs covered under Part B. The MedPAC staff offered three potential changes as a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?